scholarly journals Clinical evaluation of high intensity interval training exercise in coronary heart disease patients after percutaneous coronary intervention

Medicine ◽  
2021 ◽  
Vol 100 (14) ◽  
pp. e25472
Author(s):  
Xiaohui Cheng ◽  
Jian Huang ◽  
Jing Zhu ◽  
Hui Li ◽  
Haibo Gu
2020 ◽  
Author(s):  
Xinyue Zhang ◽  
Dongmei Xu ◽  
Guozhen Sun ◽  
Zhixin Jiang ◽  
Jinping Tian ◽  
...  

BackgroundHigh-intensity interval training, for its characteristic of short-time high oxygen-consumption exercise interphase with periods of low-intensity training or rest for recovery, is easier to persist and execute in cardiac rehabilitation. However, it is little known whether HIIT program has an advantageous effect on patients after percutaneous coronary intervention or not.MethodsRandomized controlled trials (RCTs) focusing on HIIT program in patients after PCI were searched in Cochrane Library, Web of Science Core Collection, EMbase, PubMed, China National Knowledge Infrastructure (CNKI) and SinoMed from the inception to March 24, 2020. Two reviewers conducted the literature retrieval, data extraction, and quality assessment independently. Standard Mean difference (SMD) and 95% confidence intervals (CI) were performed to summarize the effect sizes.Results6 RCTs (247 patients) met the criteria. HIIT program had a statistically significant effect on raising left ventricular ejection function (LVEF) (SMD=0.38, 95%CI[0.03, 0.73], p=0.03), VO2peak (SMD=0.94, 95%CI[0.61, 1.28], p<0.01), as well as improving the serum level of high-density lipoprotein (SMD=0.55, 95%CI[0.06, 1.03], p=0.03) and late luminal loss (SMD=−0.65, 95%CI[−1.07, −0.23], p<0.01). But HIIT had no prominent effect on improving heart rate (SMD=−0.04, 95%CI[-0.29, 0.21], p=0.73).ConclusionsHIIT program might be favorable for CAD patients after PCI by improving cardiopulmonary function, such as LVEF and VO2peak, as well as reducing late luminal loss in per stented arteries. Nevertheless, HIIT had no advantage for adjusting heart rate. More researches with rigorous methods are warranted to explore the controversy about lipid profiles.


Medicine ◽  
2020 ◽  
Vol 99 (47) ◽  
pp. e23126
Author(s):  
Filip Dosbaba ◽  
Martin Hartman ◽  
Jakub Hnatiak ◽  
Ladislav Batalik ◽  
Ondrej Ludka

Angiology ◽  
2021 ◽  
pp. 000331972110155
Author(s):  
Xiaogang Liu ◽  
Peng Zhang ◽  
Jing Zhang ◽  
Xue Zhang ◽  
Shicheng Yang ◽  
...  

The Mehran risk score (MRS) was used to classify patients with coronary heart disease and evaluate the preventive effect of alprostadil on contrast-induced nephropathy (CIN) after percutaneous coronary intervention. The patients (n = 1146) were randomized into an alprostadil and control group and then divided into 3 groups on the basis of the MRS: low-risk, moderate-risk, and high-risk groups. The primary end point was the occurrence of CIN (alprostadil + hydration vs simple hydration treatment); secondary end points included serum creatinine, blood urea nitrogen, creatinine clearance rate, cystatin C, interleukin-6, C-reactive protein, proteinuria, and differences in the incidence of major adverse events. In the low-risk, moderate-risk, and high-risk groups, the incidence of CIN in the control and alprostadil group was 2.9 versus 2.6% ( P = .832), 11.4 versus 4.9% ( P = .030), 19.1 versus 7.7% ( P = .041), respectively. Multivariate logistic regression analysis showed that alprostadil treatment was a favorable protective factor for moderate-risk and high-risk CIN patients (OR = 0.343, 95% CI: 0.124-0.951, P = .040). Alprostadil can be used as a preventive treatment for moderate- and high-risk CIN patients classified by the MRS. The reduction of CIN by alprostadil may be related to an anti-inflammatory effect.


Sign in / Sign up

Export Citation Format

Share Document